Geron Corporation (GERN) NASDAQ
1.17
-0.04(-3.31%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.17
-0.04(-3.31%)
Currency In USD
Address
919 East Hillsdale Boulevard
Foster City, CA 94404
United States of America (the)
Phone
650 473 7700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
229
First IPO Date
July 31, 1996
| Name | Title | Pay | Year Born |
| Harout Semerjian | Chief Executive Officer, President & Director | 526,355 | 1970 |
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | 307,934 | 1981 |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | 485,317 | 1977 |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 810,552 | 1967 |
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | 1M | 1967 |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | 0 | N/A |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | 0 | N/A |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Shannon Odam | Executive Vice President & Chief People Officer | 0 | 1975 |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.